Overview

A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics

Status:
Completed
Trial end date:
2017-10-17
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I study is to determine the safety of a drug called dexmedetomidine (DEX) as part of a balanced general anesthetic and sedative strategy for neonates and infants undergoing corrective cardiac surgery that requires the use of cardiopulmonary bypass for congenital cardiac problems. This study will also design and validate a dosing schema for the use of DEX as described above.
Phase:
Phase 1
Details
Lead Sponsor:
HealthCore-NERI
New England Research Institutes
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Dexmedetomidine